Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29835086 | 0.91 | MAPT (0.51) | TSHRMAPTPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL28049576 | 0.88 | MAPT (0.53) | TSHRMAPTPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL28782981 | 0.88 | ALDH1A1 (0.50) | TSHRMAPTPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL29686473 | 0.85 | TSHR (0.54) | TSHRMAPTPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL521662 | 0.85 | TSHR (0.68) | TSHRMAPTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL7111424 | 0.85 | TSHR (0.54) | TSHRMAPTPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL1185665 | 0.85 | TSHR (0.48) | TSHRMAPTPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL5427764 | 0.85 | ALDH1A1 (0.53) | TSHRMAPTPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL5572398 | 0.84 | SLC6A2 (0.56) | TSHRALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL31207307 | 0.84 | TSHR (0.53) | TSHRMAPTPOLBALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125361-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4461734-B1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC (US) | 2026-02-04 | — | — | EP | disclosed |
| EP-4480953-B1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC (US) | 2026-02-04 | — | — | EP | disclosed |
| US-20250243193-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | SYNGENE INTERNATIONAL LIMITED (IN) | 2025-07-31 | — | — | US | disclosed |
| EP-4592286-A1 | MACROCYCLIC NITROGEN-CONTAINING CROWN ETHER COMPOUND AND USE THEREOF AS PROTEIN KINASE INHIBITOR | Artivila Biopharma (CN) | 2025-07-30 | — | — | EP | disclosed |
| US-12351572-B2 | Substituted 1,2,4-triazoles as TYK2 inhibitors | ALUMIS INC. (US) | 2025-07-08 | — | — | US | disclosed |
| CN-113490664-B | TYK2 inhibitors and uses thereof | 阿鲁米斯公司 | 2025-05-16 | — | — | CN | disclosed |
| EP-4538269-A1 | SUBSTITUTED PYRIDAZINE-3-CARBOXAMIDE COMPOUND SERVING AS TYK2 INHIBITOR | Guangzhou Fermion Technology Co., Ltd. (CN) | 2025-04-16 | — | — | EP | disclosed |
| EP-4538268-A1 | PYRIDAZIN-3-CARBOXAMIDE COMPOUND AS TYK2 INHIBITOR | Guangzhou Fermion Technology Co., Ltd. (CN) | 2025-04-16 | — | — | EP | disclosed |
| WO-2025072462-A1 | SULFONAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| US-5856321-A | PREPARATION OF CARBAPENEMS | ZENECA LIMITED (GB) | 1999-01-05 | — | — | US | disclosed |
| EP-0887346-A2 | Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives, their preparation and their use as alpha1A/1L adrenoceptor agonists | F. HOFFMANN-LA ROCHE AG (CH) | 1998-12-30 | — | — | EP | disclosed |
| EP-0579826-B1 | CARBAPENEMS CONTAINING A CARBOXY SUBSTITUTED PHENYL GROUP, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES AND USE AS ANTIBIOTICS | ZENECA LTD (GB) | 1998-11-11 | — | — | EP | disclosed |
| EP-0798292-A1 | ANILINE DERIVATIVES HAVING NITROGEN MONOXIDE SYNTHASE INHIBITORY ACTIVITY | Chugai Seiyaku Kabushiki Kaisha (JP) | 1997-10-01 | — | — | EP | disclosed |
| US-5652233-A | CARBAPENICILLINS | ZENECA LIMITED (GB) | 1997-07-29 | — | — | US | disclosed |
| US-5478820-A | Carbapenem deivatives; bactericides | ZENECA LTD. (GB) | 1995-12-26 | — | — | US | disclosed |
| EP-0579826-A1 | CARBAPENEMS CONTAINING A CARBOXY SUBSTITUTED PHENYL GROUP, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES AND USE AS ANTIBIOTICS | ZENECA LIMITED (GB) | 1994-01-26 | — | — | EP | disclosed |
| WO-1993015078-A1 | CARBAPENEMS CONTAINING A CARBOXY SUBSTITUTED PHENYL GROUP, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES AND USE AS ANTIBIOTICS | ZENECA LIMITED (GB) | 1993-08-05 | — | — | WO | disclosed |
| US-4470977-A | 3-CHLORO-N-(1-ETHYL-2-PYRROLIDINYLMETHYL2-METHOXYBENZAMIDE | ADRIA LABORATORIES, INC. (US) | 1984-09-11 | — | — | US | disclosed |
| EP-0105599-A1 | Antiemetic and antipsychotic agents | ADRIA LABORATORIES, INC. (US) | 1984-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12351572-B2 | Substituted 1,2,4-triazoles as TYK2 inhibitors | TYK2, JAK1, JAK3 | TSHR 425/4885MAPT 876/4885POLB 3747/4885 |
| US-20250243193-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | IFNG, IFNAR1, TYK2 | TSHR 749/4885MAPT 3440/4885POLB 2458/4885 |
| US-20260125361-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK3 | TSHR 473/4885MAPT 454/4885POLB 4214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.